Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Thirupandiyur S. Udayakumar(Fox Chase Cancer Center), Alan Pollack(Sylvester Comprehensive Cancer Center), Radka Stoyanova(Sylvester Comprehensive Cancer Center), Kerry L. Burnstein(University of Miami), Mohammed M. Shareef(University of Miami), Zhaomei Mu(Thomas Jefferson University), Sakhi Philip(Sylvester Comprehensive Cancer Center)
Cited by 0
Related Papers
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
|Pharmacological Reviews|2006|430
Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration.
|PubMed|2003|131
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
|European Urology|2017|130
MDM2 and Ki-67 Predict for Distant Metastasis and Mortality in Men Treated With Radiotherapy and Androgen Deprivation for Prostate Cancer: RTOG 92-02
|Journal of Clinical Oncology|2009|102